GlassScriptPhysician profile
Howard A Stein
NPI 1992887954
$6,377.37
in general payments reported to CMS, 2019-2025
23 companies · $558 in 2025
The $558 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $780 · 2021: $1,025 · 2022: $1,099 · 2023: $694 · 2024: $861 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Gift: $327 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.47 |
| Gift | $327.24 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,033.38 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $749.67 | 2020-2025 | Viberzi, Linzess, Skyrizi |
| Braintree Laboratories, INC. | $718.59 | 2020-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $413.79 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $333.38 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $305.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.14 | 2019-2021 | |
| Celgene Corporation | $240.15 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $234.71 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $189.96 | 2019-2020 | |
| Genzyme Corporation | $185.00 | 2019 | |
| Redhill Biopharma INC. | $149.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.92 | 2021 | |
| Boston Scientific Corporation | $82.96 | 2019 | |
| Celltrion USA INC. | $81.82 | 2024-2025 | Vegzelma |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.31 | 2020-2022 | |
| Laborie Medical Technologies Corp. | $67.25 | 2024 | Renovarp |
| Janssen Biotech, INC. | $53.38 | 2022-2024 | Tremfya, Stelara |
| Evoke Pharma, INC. | $26.00 | 2022-2023 | Gimoti |
| Madrigal Pharmaceuticals | $20.67 | 2025 | Rezdiffra |
| Medtronic, INC. | $18.63 | 2021 | |
| Qol Medical, LLC | $18.20 | 2019 | |
| Alfasigma USA, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.